Bliss GVS Pharma is the world’s largest specialist in suppositories and pessaries - the bullet-shaped medicines absorbed rapidly for patients who cannot swallow pills - built over four decades from a single Indian plant into a supplier of more than 400 branded formulations across over 60 countries. Incorporated in 1984 as Bliss Chemicals and Pharmaceuticals and merged with GVS Labs in 2006, the company turned a niche dosage form into a competitive moat: standard pill-makers rarely invest in the separate production lines and regulatory know-how that suppositories demand, so Bliss GVS became the go-to manufacturer for global distributors and institutional buyers who need these products at scale. That recurring logic - pick a hard-to-replicate speciality, build capacity ahead of demand, and sell to partners who handle the last mile - explains everything else the company does.
Business segments
Two engines that feed each other - a specialised manufacturing platform for suppositories and pessaries that few rivals can match, and a broad branded-generics portfolio that rides the same factories and distribution relationships into over 60 countries.
1. Suppositories and pessaries: the niche that competitors cannot easily copy
With two dedicated plants producing close to a billion units a year and regulatory approvals from every major health authority, the company has built a specialised entry barrier that turns a small dosage form into a global franchise.
- India’s first EU-GMP-certified suppository maker - the Palghar facility was the first in India to win EU-GMP certification for suppositories, and it later added US FDA approval in 2024, giving the company a head start that newer entrants would need years to match.
- Capacity that dwarfs the field - Unit 2 at Palghar can make 380 million suppositories and pessaries a year, and Unit 3 adds another 576 million, so the combined output of roughly 956 million units annually is among the largest dedicated suppository capacities anywhere.
- Formulations that solve real medical gaps - the portfolio spans anti-malarial, anti-haemorrhoidal, anti-fungal, anti-emetic and antidepressant suppositories, including an artesunate suppository that reduces malaria mortality by about 25% in children under six and is supplied to NGOs across Africa.
- A moat built on know-how, not patents - suppositories require separate manufacturing lines, different quality-control protocols and specialised regulatory filings, so the company’s four decades of accumulated expertise act as a barrier that standard oral-solid-dose manufacturers rarely cross.
2. Branded generics: the broad portfolio that fills the same trucks
Over 150 branded formulations across more than 50 therapeutic segments are sold primarily to distributors and institutional buyers in Africa, where the company’s anti-malarial and dermatology brands hold leadership positions.
- Africa-first, distributor-led - more than 80% of sales volume comes from sub-Saharan Africa, where the company sells to dealers and distributors who account for 96.6% of total sales, making it a B2B manufacturer rather than a consumer-facing pharma company.
- Flagship brands that doctors recognise - Lonart (anti-malarial) is widely recognised for its proven efficacy and reliable performance, while Funbact commands a leadership position in dermatological anti-fungals, and P-Alaxin and Lofnac hold top spots in multiple sub-Saharan countries.
- Sixteen dosage forms from the same factory network - tablets, capsules, syrups, creams, ointments, liquids, sachets and dry syrups are all made in-house, so the company can offer distributors a one-stop basket rather than a single product line.
- Contract manufacturing for global pharma companies - the same plants that make Bliss GVS’s own brands also produce for leading international and domestic pharmaceutical companies, which spreads fixed costs and deepens relationships with buyers who later source their own-label products.
Manufacturing and R&D backbone
Six plants in Maharashtra, a DSIR-certified R&D centre in Mumbai, and a quality system that holds over 25 international regulatory accreditations form the shared engine behind both business segments.
- Six plants, one cluster - all manufacturing units are in Maharashtra, with Unit 5 at Vevoor alone capable of producing 2,300 million tablets and 1,800 million capsules a year, while Unit 4 adds 200 million units of ointments, creams and gels.
- Regulatory approvals as a sales licence - the facilities hold accreditations from US FDA, EU GMP, WHO GMP, TGA Australia, Health Canada and over 25 other authorities, which means products made here can be registered in most markets without requalification.
- R&D that shortens the lab-to-factory distance - the DSIR-certified Mumbai centre houses over 85 scientists and runs a cross-functional stage-gate process that links formulation development directly to commercial teams, so new products are designed with a buyer already in mind.
Group structure and partners
A Singapore holding company, a partly-owned Indian subsidiary for creams and ointments, and two new African subsidiaries incorporated in 2025 form a structure designed to hold international registrations and get closer to end-markets.
- Singapore as the international hub - Bliss GVS International Pte. Ltd. is the wholly-owned subsidiary that holds the overseas operating entities, including the newly incorporated Theralife Pharma Ltd in Kenya and Theralife Pharma RDC in the Democratic Republic of the Congo.
- Kremoint Pharma for dermatology manufacturing - the 70%-owned Indian subsidiary at Ambernath makes creams and ointments, adding semi-solid capacity that complements the suppository and tablet plants.
- A change of control in progress - in May 2026, Anupam Rasayan India signed a share purchase agreement to acquire 43.30% of Bliss GVS Pharma from promoter and non-promoter shareholders, with a mandatory open offer for up to 26% more, which will make Anupam Rasayan the new promoter upon closing.
- Promoter family at the helm until closing - the three executive directors - Mrs. Shruti Vishal Rao, Dr. Vibha Gagan Sharma and Mr. Gagan Harsh Sharma - are related by marriage and sibling ties, and together the promoter group holds 35.36% of the company as of March 2026.